外泌体PD-L1在肿瘤免疫治疗中的研究进展

近年来,肿瘤免疫治疗取得了重大的进步,目前以程序性细胞死亡蛋白1(programmed cell death protein-1,PD-1)/程序性细胞死亡蛋白-配体1(programmed cell death protein-ligand 1,PD-L1)抑制剂为代表的新型免疫治疗临床应用如火如荼进行中,但在PD-...

Research progress of exosomal PD-L1 in tumor immunotherapy

Currently,major progress has been made in tumor immunotherapy,the new immunotherapy represented by programmed cell death protein-1(PD-1)/programmed cell death protein-ligand 1(PD-L1)inhibitors is in full momentum of clinical application.However,in the application of PD-1/PD-L1 inhibitors.There are significant differences in efficacy between different patients and different tumor types.The latest study found that exosomal PD-L1 can explain this difference in efficacy.The main mechanism is that exosomal PD-L1 can replace cell PD-L1 and inhibit T cell activation.Meanwhile,it can also transfer functional PD-L1 to other cells to generate immune resistance or tolerance,affecting the outcome of PD-1/PD-L1 inhibitors treatment.And the relationship between exosomal PD-L1 and tumor immunotherapy is briefly introduced in this paper.